A subgroup of patients is known to have poor responses to TKI therapy or to develop resistance to treatment in a longer follow-up.43 Our study implies an interesting possibility that the combination of Imatinib and TGF-β agonists is a potential alternative therapy for CML. Here, TGFB1 is linked to chronic myelogenous leukemia, BCR-ABL1 positive.